In addition, CSF (Aβ1-42, T-Tau, P-Tau) and plasma (p-tau181, Aβ42/40 ratio) from selected patients were collected and analyzed together, and it was found that changes in biomarkers may be sequential in AD patients [22]. The gene discussed is MAPT; the disease is Alzheimer disease.